Rockwell Medical Inc (NASDAQ:RMTI)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $3.54 and last traded at $3.59, with a volume of 457700 shares trading hands. The stock had previously closed at $3.86.
Several equities analysts have recently issued reports on RMTI shares. Ifs Securities reissued an “outperform” rating and set a $11.00 price target on shares of Rockwell Medical in a report on Friday, October 19th. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 18th. Finally, ValuEngine raised shares of Rockwell Medical from a “hold” rating to a “buy” rating in a report on Tuesday, September 4th.
The firm has a market cap of $198.54 million, a PE ratio of -8.59 and a beta of 1.42.
Several institutional investors and hedge funds have recently made changes to their positions in RMTI. Sigma Investment Counselors Inc. boosted its holdings in shares of Rockwell Medical by 24.3% during the third quarter. Sigma Investment Counselors Inc. now owns 86,834 shares of the company’s stock valued at $366,000 after acquiring an additional 17,000 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Rockwell Medical by 13.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 108,942 shares of the company’s stock worth $538,000 after purchasing an additional 13,042 shares during the period. Raymond James & Associates lifted its holdings in Rockwell Medical by 59.0% in the second quarter. Raymond James & Associates now owns 128,276 shares of the company’s stock worth $632,000 after purchasing an additional 47,600 shares during the period. Finally, BlackRock Inc. lifted its holdings in Rockwell Medical by 0.8% in the third quarter. BlackRock Inc. now owns 3,221,245 shares of the company’s stock worth $13,593,000 after purchasing an additional 25,322 shares during the period. 22.15% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3928914/rockwell-medical-rmti-hits-new-52-week-low-at-3-54.html.
About Rockwell Medical (NASDAQ:RMTI)
Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.
Recommended Story: Asset Allocation
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.